174 related articles for article (PubMed ID: 17617204)
1. Diagnostic utility of interleukin-6 (IL-6) for primary bile duct cancer and changes in serum IL-6 levels following photodynamic therapy.
Cheon YK; Cho YD; Moon JH; Jang JY; Kim YS; Kim YS; Lee MS; Lee JS; Shim CS
Am J Gastroenterol; 2007 Oct; 102(10):2164-70. PubMed ID: 17617204
[TBL] [Abstract][Full Text] [Related]
2. Targeting IL-6 in cholangiocarcinoma therapy.
Mott JL; Gores GJ
Am J Gastroenterol; 2007 Oct; 102(10):2171-2. PubMed ID: 17897336
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant photodynamic therapy for bile duct carcinoma after surgery: a preliminary study.
Nanashima A; Yamaguchi H; Shibasaki S; Ide N; Sawai T; Tsuji T; Hidaka S; Sumida Y; Nakagoe T; Nagayasu T
J Gastroenterol; 2004 Nov; 39(11):1095-101. PubMed ID: 15580404
[TBL] [Abstract][Full Text] [Related]
4. The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis.
Patel AH; Harnois DM; Klee GG; LaRusso NF; Gores GJ
Am J Gastroenterol; 2000 Jan; 95(1):204-7. PubMed ID: 10638584
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic role of serum interleukin 6 and CA 19-9 in patients with cholangiocarcinoma.
Tangkijvanich P; Thong-ngam D; Theamboonlers A; Hanvivatvong O; Kullavanijaya P; Poovorawan Y
Hepatogastroenterology; 2004; 51(55):15-9. PubMed ID: 15011822
[TBL] [Abstract][Full Text] [Related]
6. Enhanced detection of cholangiocarcinoma with serum trypsinogen-2 in patients with severe bile duct strictures.
Lempinen M; Isoniemi H; Mäkisalo H; Nordin A; Halme L; Arola J; Höckerstedt K; Stenman UH
J Hepatol; 2007 Nov; 47(5):677-83. PubMed ID: 17640760
[TBL] [Abstract][Full Text] [Related]
7. The value of biliary fibronectin for diagnosis of cholangiocarcinoma.
Chen CY; Lin XZ; Tsao HC; Shiesh SC
Hepatogastroenterology; 2003; 50(52):924-7. PubMed ID: 12845951
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of serum MUC5AC mucin in patients with cholangiocarcinoma.
Boonla C; Wongkham S; Sheehan JK; Wongkham C; Bhudhisawasdi V; Tepsiri N; Pairojkul C
Cancer; 2003 Oct; 98(7):1438-43. PubMed ID: 14508831
[TBL] [Abstract][Full Text] [Related]
9. Biliary carcinoembryonic antigen levels are a marker for cholangiocarcinoma.
Nakeeb A; Lipsett PA; Lillemoe KD; Fox-Talbot MK; Coleman J; Cameron JL; Pitt HA
Am J Surg; 1996 Jan; 171(1):147-52; discussion 152-3. PubMed ID: 8554130
[TBL] [Abstract][Full Text] [Related]
10. Palliation of nonresectable bile duct cancer: improved survival after photodynamic therapy.
Zoepf T; Jakobs R; Arnold JC; Apel D; Riemann JF
Am J Gastroenterol; 2005 Nov; 100(11):2426-30. PubMed ID: 16279895
[TBL] [Abstract][Full Text] [Related]
11. An interleukin-6 (IL-6) receptor polymorphism affecting serum levels of IL-6 does not increase the risk of cholangiocarcinoma in primary sclerosing cholangitis.
Melum E; Karlsen TH; Bergquist A; Schrumpf E; Boberg KM
Am J Gastroenterol; 2008 Apr; 103(4):1045; author reply 1045-6. PubMed ID: 18397431
[No Abstract] [Full Text] [Related]
12. Unresectable cholangiocarcinoma: comparison of survival in biliary stenting alone versus stenting with photodynamic therapy.
Kahaleh M; Mishra R; Shami VM; Northup PG; Berg CL; Bashlor P; Jones P; Ellen K; Weiss GR; Brenin CM; Kurth BE; Rich TA; Adams RB; Yeaton P
Clin Gastroenterol Hepatol; 2008 Mar; 6(3):290-7. PubMed ID: 18255347
[TBL] [Abstract][Full Text] [Related]
13. Serum interleukin-6 and hepatocyte growth factor levels in patients after hepatectomy.
Chijiiwa K; Saiki S; Tanaka M
Hepatogastroenterology; 2002; 49(44):467-71. PubMed ID: 11995475
[TBL] [Abstract][Full Text] [Related]
14. Marked elevation of serum interleukin-6 in patients with cholangiocarcinoma: validation of utility as a clinical marker.
Goydos JS; Brumfield AM; Frezza E; Booth A; Lotze MT; Carty SE
Ann Surg; 1998 Mar; 227(3):398-404. PubMed ID: 9527063
[TBL] [Abstract][Full Text] [Related]
15. Serum levels of interleukin-6 in patients with primary head and neck squamous cell carcinoma.
Riedel F; Zaiss I; Herzog D; Götte K; Naim R; Hörmann K
Anticancer Res; 2005; 25(4):2761-5. PubMed ID: 16080523
[TBL] [Abstract][Full Text] [Related]
16. Serum interleukin-8 level is a more sensitive marker than serum interleukin-6 level in monitoring the disease activity of oral lichen planus.
Sun A; Wang JT; Chia JS; Chiang CP
Br J Dermatol; 2005 Jun; 152(6):1187-92. PubMed ID: 15948980
[TBL] [Abstract][Full Text] [Related]
17. Is a raised CA 19-9 level diagnostic for a cholangiocarcinoma in patients with no history of sclerosing cholangitis ?
John AR; Haghighi KS; Taniere P; Esmat ME; Tan YM; Bramhall SR
Dig Surg; 2006; 23(5-6):319-24. PubMed ID: 17170527
[TBL] [Abstract][Full Text] [Related]
18. A new mucin antibody/enzyme-linked lectin-sandwich assay of serum MUC5AC mucin for the diagnosis of cholangiocarcinoma.
Bamrungphon W; Prempracha N; Bunchu N; Rangdaeng S; Sandhu T; Srisukho S; Boonla C; Wongkham S
Cancer Lett; 2007 Mar; 247(2):301-8. PubMed ID: 16793202
[TBL] [Abstract][Full Text] [Related]
19. Interleukin 6 in bile as an indicator of liver function after hepatectomy in patients with biliary tract carcinoma.
Maeda A; Nagino M; Takeuchi E; Sano T; Kurumiya Y; Nimura Y
Br J Surg; 1999 Apr; 86(4):458-64. PubMed ID: 10215814
[TBL] [Abstract][Full Text] [Related]
20. Serum levels of variants of transthyretin down-regulation in cholangiocarcinoma.
Liu L; Wang J; Liu B; Dai S; Wang X; Chen J; Huang L; Xiao X; He D
J Cell Biochem; 2008 Jun; 104(3):745-55. PubMed ID: 18275060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
